Innovations and recent trends in the treatment of ADHD

Vishal Madaan, Shannon Kinnan, Joan Daughton, Christopher J Kratochvil

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Initiatives to develop better-tolerated, more efficacious pharmacological agents with improved drug delivery systems have driven recent research in attention-deficit hyperactivity disorder (ADHD). While stimulants are the primary pharmacotherapy for ADHD, these drugs have a limited duration of action and a subset of patients will either fail to respond to these medications or have side effects that preclude their use. The development of atomoxetine, the first nonstimulant approved for ADHD, has been followed by additional innovative research, such as the methylphenidate transdermal system, modafinil, NRP-104 and cholinergic agents. This review highlights some of the recent trends in ADHD treatment and the current status of promising treatment options that may help to shape the future of ADHD treatment.

Original languageEnglish (US)
Pages (from-to)1375-1385
Number of pages11
JournalExpert Review of Neurotherapeutics
Volume6
Issue number9
DOIs
StatePublished - Sep 1 2006

Fingerprint

Attention Deficit Disorder with Hyperactivity
Therapeutics
Methylphenidate
Drug Delivery Systems
Research
Cholinergic Agents
Pharmacology
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Atomoxetine
  • Attention-deficit hyperactivity disorder
  • Modafinil
  • NRP-104
  • Pharmacotherapy
  • Stimulants
  • Transdermal

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Innovations and recent trends in the treatment of ADHD. / Madaan, Vishal; Kinnan, Shannon; Daughton, Joan; Kratochvil, Christopher J.

In: Expert Review of Neurotherapeutics, Vol. 6, No. 9, 01.09.2006, p. 1375-1385.

Research output: Contribution to journalReview article

Madaan, Vishal ; Kinnan, Shannon ; Daughton, Joan ; Kratochvil, Christopher J. / Innovations and recent trends in the treatment of ADHD. In: Expert Review of Neurotherapeutics. 2006 ; Vol. 6, No. 9. pp. 1375-1385.
@article{ce1940c9171946cba952a6a972c217db,
title = "Innovations and recent trends in the treatment of ADHD",
abstract = "Initiatives to develop better-tolerated, more efficacious pharmacological agents with improved drug delivery systems have driven recent research in attention-deficit hyperactivity disorder (ADHD). While stimulants are the primary pharmacotherapy for ADHD, these drugs have a limited duration of action and a subset of patients will either fail to respond to these medications or have side effects that preclude their use. The development of atomoxetine, the first nonstimulant approved for ADHD, has been followed by additional innovative research, such as the methylphenidate transdermal system, modafinil, NRP-104 and cholinergic agents. This review highlights some of the recent trends in ADHD treatment and the current status of promising treatment options that may help to shape the future of ADHD treatment.",
keywords = "Atomoxetine, Attention-deficit hyperactivity disorder, Modafinil, NRP-104, Pharmacotherapy, Stimulants, Transdermal",
author = "Vishal Madaan and Shannon Kinnan and Joan Daughton and Kratochvil, {Christopher J}",
year = "2006",
month = "9",
day = "1",
doi = "10.1586/14737175.6.9.1375",
language = "English (US)",
volume = "6",
pages = "1375--1385",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "9",

}

TY - JOUR

T1 - Innovations and recent trends in the treatment of ADHD

AU - Madaan, Vishal

AU - Kinnan, Shannon

AU - Daughton, Joan

AU - Kratochvil, Christopher J

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Initiatives to develop better-tolerated, more efficacious pharmacological agents with improved drug delivery systems have driven recent research in attention-deficit hyperactivity disorder (ADHD). While stimulants are the primary pharmacotherapy for ADHD, these drugs have a limited duration of action and a subset of patients will either fail to respond to these medications or have side effects that preclude their use. The development of atomoxetine, the first nonstimulant approved for ADHD, has been followed by additional innovative research, such as the methylphenidate transdermal system, modafinil, NRP-104 and cholinergic agents. This review highlights some of the recent trends in ADHD treatment and the current status of promising treatment options that may help to shape the future of ADHD treatment.

AB - Initiatives to develop better-tolerated, more efficacious pharmacological agents with improved drug delivery systems have driven recent research in attention-deficit hyperactivity disorder (ADHD). While stimulants are the primary pharmacotherapy for ADHD, these drugs have a limited duration of action and a subset of patients will either fail to respond to these medications or have side effects that preclude their use. The development of atomoxetine, the first nonstimulant approved for ADHD, has been followed by additional innovative research, such as the methylphenidate transdermal system, modafinil, NRP-104 and cholinergic agents. This review highlights some of the recent trends in ADHD treatment and the current status of promising treatment options that may help to shape the future of ADHD treatment.

KW - Atomoxetine

KW - Attention-deficit hyperactivity disorder

KW - Modafinil

KW - NRP-104

KW - Pharmacotherapy

KW - Stimulants

KW - Transdermal

UR - http://www.scopus.com/inward/record.url?scp=33750182472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750182472&partnerID=8YFLogxK

U2 - 10.1586/14737175.6.9.1375

DO - 10.1586/14737175.6.9.1375

M3 - Review article

VL - 6

SP - 1375

EP - 1385

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 9

ER -